158
Views
14
CrossRef citations to date
0
Altmetric
Review

Management of Huntington’s disease: role of tetrabenazine

, &
Pages 123-129 | Published online: 21 Mar 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Joseph Jankovic & Kathleen Clarence-Smith. (2011) Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Review of Neurotherapeutics 11:11, pages 1509-1523.
Read now

Articles from other publishers (13)

Samantha Hughes, Maritza van Dop, Nikki Kolsters, David van de Klashorst, Anastasia Pogosova & Anouk M. Rijs. (2022) Using a Caenorhabditis elegans Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency. Pharmaceuticals 15:5, pages 512.
Crossref
Pei Teng Lum, Mahendran Sekar, Siew Hua Gan, Srinivasa Reddy Bonam & Mohd. Farooq Shaikh. (2021) Protective Effect of Natural Products against Huntington’s Disease: An Overview of Scientific Evidence and Understanding Their Mechanism of Action. ACS Chemical Neuroscience 12:3, pages 391-418.
Crossref
Manuela Bozzi & Francesca Sciandra. (2020) Molecular Mechanisms Underlying Muscle Wasting in Huntington’s Disease. International Journal of Molecular Sciences 21:21, pages 8314.
Crossref
Ashok Kumar, Vijay Kumar, Kritanjali Singh, Sukesh Kumar, You-Sam Kim, Yun-Mi Lee & Jong-Joo Kim. (2020) Therapeutic Advances for Huntington’s Disease. Brain Sciences 10:1, pages 43.
Crossref
Anindita Deb, Samuel Frank & Claudia M. Testa. 2017. Huntington Disease. Huntington Disease 199 207 .
Susana Almeida, Marco G. Alves, Mário Sousa, Pedro F. Oliveira & Branca M. Silva. (2016) Are Polyphenols Strong Dietary Agents Against Neurotoxicity and Neurodegeneration?. Neurotoxicity Research 30:3, pages 345-366.
Crossref
Joy Chakraborty, Raghavendra Singh, Debashis Dutta, Amit Naskar, Usha Rajamma & Kochupurackal P. Mohanakumar. (2014) Quercetin Improves Behavioral Deficiencies, Restores Astrocytes and Microglia, and Reduces Serotonin Metabolism in 3-Nitropropionic Acid-Induced Rat Model of Huntington's Disease. CNS Neuroscience & Therapeutics 20:1, pages 10-19.
Crossref
Amanda-Amrita D. Lakraj, Bahman Jabbari & Duarte G. Machado. 2014. Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics. Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics 335 348 .
Abdul Qayyum Rana & Peter HederaAbdul Qayyum Rana & Peter Hedera. 2014. Differential Diagnosis of Movement Disorders in Clinical Practice. Differential Diagnosis of Movement Disorders in Clinical Practice 69 85 .
S.J. Podurgiel, E.J. Nunes, S.E. Yohn, J. Barber, A. Thompson, M. Milligan, C.A. Lee, L. López-Cruz, M. Pardo, O. Valverde, C. Lendent, Y. Baqi, C.E. Müller, M. Correa & J.D. Salamone. (2013) The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor. Neuroscience 250, pages 507-519.
Crossref
Simon P. Brooks & Stephen B. Dunnett. 2015. Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease 101 133 .
Jack J. Chen, William G. Ondo, Khashayar Dashtipour & David M. Swope. (2012) Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature. Clinical Therapeutics 34:7, pages 1487-1504.
Crossref
Lesley J. Scott. (2011) Tetrabenazine. CNS Drugs 25:12, pages 1073-1085.
Crossref